

9F, No. 108, Jhouzih St.,Taipei, Taiwan Tel: + 886-2-8751-1888 Fax: + 886-2-6602-1218 E-mail: sales@abnova.com

Datasheet

EIF4G2 monoclonal antibody (M01), clone 3B5

Catalog Number: H00001982-M01

Regulatory Status: For research use only (RUO)

Product Description: Mouse monoclonal antibody raised against a partial recombinant EIF4G2.

Clone Name: 3B5

Immunogen: EIF4G2 (NP_001409, 811 a.a. ~ 889 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

Sequence:

SFKPVMQKFLHDHVDLQVSALYALQVHCYNSNFPKG MLLRFFVHFYDMEIIEEEAFLAWKEDITQEFPGKGKALF QVNQ

Host: Mouse

Reactivity: Human, Rat

Applications: ELISA, IHC-P, S-ELISA, WB-Ce, WB-Re (See our web site product page for detailed applications information)

Protocols: See our web site at

http://www.abnova.com/support/protocols.asp or product page for detailed protocols

Isotype: IgG1 Kappa

Storage Buffer: In 1x PBS, pH 7.4

Storage Instruction: Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.

Entrez GenelD: 1982

Gene Symbol: EIF4G2

Gene Alias: AAG1, DAP5, FLJ41344, NAT1, p97

Gene Summary: Translation initiation is mediated by specific recognition of the cap structure by eukaryotic translation initiation factor 4F (eIF4F), which is a cap binding protein complex that consists of three subunits:

eIF4A, eIF4E and eIF4G. The protein encoded by this gene shares similarity with the C-terminal region of eIF4G that contains the binding sites for eIF4A and eIF3; eIF4G, in addition, contains a binding site for eIF4E at the N-terminus. Unlike eIF4G, which supports cap-dependent and independent translation, this gene product functions as a general repressor of translation by forming translationally inactive complexes. In vitro and in vivo studies indicate that translation of this mRNA initiates exclusively at a non-AUG (GUG) codon. Alternatively spliced transcript variants encoding different isoforms of this gene have been described. [provided by RefSeq]

References:

1. The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets. Katsogiannou M, Andrieu C, Baylot V, Baudot A, Dusetti NJ, Gayet O, Finetti P, Garrido C, Birnbaum D, Bertucci F, Brun C, Rocchi P Mol Cell Proteomics. 2014 Oct 2. pii: mcp.M114.041228.